India's Elder Pharma to enter EU markets; comment on GSK Indian OTC moves
Indian drugmaker Elder Pharmaceuticals says it is ready to enter the European Union market following receipt of Certificate of Suitability (CoS) from European Directorate for the Quality of Medicines and Healthcare for its active pharmaceutical ingredient (API) diosmin, an oral phlebotropic drug used in the treatment of venous system related diseases, reports the Indian Express.
"The recognition by EDQM will immensely help the company to enter the regulated markets of European Union.... CoS approval for diosmin API will also enable the company to expand its global market share," Elder Pharma joint managing director Alok Saxena told PTI in India.
"We have already received accreditation from Ministry of Health-Japan for our Active Pharmaceutical Ingredients (API) plant at Patalganga in Maharashtra," he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze